Anacetrapib
WikiDoc Resources for Anacetrapib |
Articles |
---|
Most recent articles on Anacetrapib Most cited articles on Anacetrapib |
Media |
Powerpoint slides on Anacetrapib |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Anacetrapib at Clinical Trials.gov Clinical Trials on Anacetrapib at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Anacetrapib
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Anacetrapib Discussion groups on Anacetrapib Patient Handouts on Anacetrapib Directions to Hospitals Treating Anacetrapib Risk calculators and risk factors for Anacetrapib
|
Healthcare Provider Resources |
Causes & Risk Factors for Anacetrapib |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Anacetrapib (MK-0859, Merck) is a drug being developed to treat hypercholesterolemia (elevated cholesterol levels) and prevent cardiovascular disease.